Cantor Fitzgerald reiterates Overweight rating on Precigen stock

Precigen Inc. (PGEN) has secured full FDA approval for PAPZIMEOS, the first and only approved therapy for recurrent respiratory papillomatosis, with a wholesale acquisition cost of $460,000 per treatment cycle. This significant milestone has prompted positive analyst reactions, including Cantor Fitzgerald reiterating an Overweight rating and updating its model to a $1.7-1.8 billion equity valuation, while other firms also raised price targets. Despite recent intraday profit-taking, PGEN shares remain up 163% year-to-date, and the company has solidified its commercialization strategy with a supply agreement for PAPZIMEOS manufacturing with Catalent, positioning it to capitalize on a substantial revenue opportunity.

Analysis

Precigen Inc. has achieved a significant regulatory and commercial milestone with the full FDA approval of PAPZIMEOS, establishing it as the first and only approved therapy for recurrent respiratory papillomatosis (RRP). This de-risking event is supported by a clear commercialization strategy, including a wholesale acquisition cost of $460,000 per treatment cycle and a strategic manufacturing supply agreement with Catalent, effective August 2025. The market has reacted strongly, with the stock delivering a 163% year-to-date return. Despite a recent 8-9% intraday pullback, attributed to profit-taking and debate over future execution, the share price remains 40-45% above pre-approval levels, outperforming the flat broader biotech sector (XBI). Analyst sentiment is firmly positive, with Cantor Fitzgerald reiterating an Overweight rating and modeling a discounted cash flow valuation of $1.7-1.8 billion, approximately 3.3 times its estimated peak sales. This is further corroborated by H.C. Wainwright and Citizens JMP, who have reiterated a Buy rating and raised price targets to $8.50 and $8.00, respectively, validating the company's pricing and launch strategy.

Key Decisions for Investors

• Given the FDA approval for PAPZIMEOS establishes a monopoly in the RRP market with a significant price point, investors should evaluate the company's long-term revenue stream now that a primary regulatory hurdle is cleared.
• It is critical to monitor the initial launch and commercial uptake of PAPZIMEOS, as successful execution is now the key variable to justify the company's valuation and overcome the market debate that contributed to recent profit-taking.
• Despite the positive outlook, investors should remain mindful of the stock's significant 163% year-to-date appreciation and recent volatility, suggesting a disciplined approach to entry points is warranted.